Re-challenge with pemetrexed in advanced mesothelioma: A multi-institutional experience

Alessandra Bearz, Renato Talamini, Gilda Rossoni, Antonio Santo, Vincenzo De Pangher, Gianpiero Fasola, Francesco Rosetti, Adolfo Favaretto, Vanesa Gregorc, Massimiliano Berretta, Sandra Santarossa, Eleonora Berto, Umberto Tirelli

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Background: Although first-line therapy for patients affected by advanced mesothelioma is well established, there is a lack of data regarding the impact of second-line treatment. Methods. We retrospectively collected data of patients affected by advanced mesothelioma, already treated with first-line therapy based on pemetrexed and platin, with a response (partial response or stable disease) lasting at least 6 months, and re-treated with a pemetrexed-based therapy at progression. The primary objective was to describe time to progression and overall survival after re-treatment. Results: Overall across several Italian oncological Institutions we found 30 patients affected by advanced mesothelioma, in progression after a 6-month lasting clinical benefit following a first-line treatment with cisplatin and pemetrexed, and re-challenged with a pemetrexed-based therapy. In these patients we found a disease control rate of 66%, with reduction of pain in 43% of patients. Overall time to progression and survival were promising for a second-line setting of patients with advanced mesothelioma, being 5.1 and 13.6 months, respectively. Conclusions: In our opinion, when a patient has a long-lasting benefit from previous treatment with pemetrexed combined with a platin compound, the same treatment should be offered at progression.

Original languageEnglish
Article number482
JournalBMC Research Notes
Volume5
DOIs
Publication statusPublished - 2012

Fingerprint

Pemetrexed
Mesothelioma
Disease control
Therapeutics
Cisplatin
Survival

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Bearz, A., Talamini, R., Rossoni, G., Santo, A., De Pangher, V., Fasola, G., ... Tirelli, U. (2012). Re-challenge with pemetrexed in advanced mesothelioma: A multi-institutional experience. BMC Research Notes, 5, [482]. https://doi.org/10.1186/1756-0500-5-482

Re-challenge with pemetrexed in advanced mesothelioma : A multi-institutional experience. / Bearz, Alessandra; Talamini, Renato; Rossoni, Gilda; Santo, Antonio; De Pangher, Vincenzo; Fasola, Gianpiero; Rosetti, Francesco; Favaretto, Adolfo; Gregorc, Vanesa; Berretta, Massimiliano; Santarossa, Sandra; Berto, Eleonora; Tirelli, Umberto.

In: BMC Research Notes, Vol. 5, 482, 2012.

Research output: Contribution to journalArticle

Bearz, A, Talamini, R, Rossoni, G, Santo, A, De Pangher, V, Fasola, G, Rosetti, F, Favaretto, A, Gregorc, V, Berretta, M, Santarossa, S, Berto, E & Tirelli, U 2012, 'Re-challenge with pemetrexed in advanced mesothelioma: A multi-institutional experience', BMC Research Notes, vol. 5, 482. https://doi.org/10.1186/1756-0500-5-482
Bearz, Alessandra ; Talamini, Renato ; Rossoni, Gilda ; Santo, Antonio ; De Pangher, Vincenzo ; Fasola, Gianpiero ; Rosetti, Francesco ; Favaretto, Adolfo ; Gregorc, Vanesa ; Berretta, Massimiliano ; Santarossa, Sandra ; Berto, Eleonora ; Tirelli, Umberto. / Re-challenge with pemetrexed in advanced mesothelioma : A multi-institutional experience. In: BMC Research Notes. 2012 ; Vol. 5.
@article{306d52563d5346889427e2870d85a34b,
title = "Re-challenge with pemetrexed in advanced mesothelioma: A multi-institutional experience",
abstract = "Background: Although first-line therapy for patients affected by advanced mesothelioma is well established, there is a lack of data regarding the impact of second-line treatment. Methods. We retrospectively collected data of patients affected by advanced mesothelioma, already treated with first-line therapy based on pemetrexed and platin, with a response (partial response or stable disease) lasting at least 6 months, and re-treated with a pemetrexed-based therapy at progression. The primary objective was to describe time to progression and overall survival after re-treatment. Results: Overall across several Italian oncological Institutions we found 30 patients affected by advanced mesothelioma, in progression after a 6-month lasting clinical benefit following a first-line treatment with cisplatin and pemetrexed, and re-challenged with a pemetrexed-based therapy. In these patients we found a disease control rate of 66{\%}, with reduction of pain in 43{\%} of patients. Overall time to progression and survival were promising for a second-line setting of patients with advanced mesothelioma, being 5.1 and 13.6 months, respectively. Conclusions: In our opinion, when a patient has a long-lasting benefit from previous treatment with pemetrexed combined with a platin compound, the same treatment should be offered at progression.",
author = "Alessandra Bearz and Renato Talamini and Gilda Rossoni and Antonio Santo and {De Pangher}, Vincenzo and Gianpiero Fasola and Francesco Rosetti and Adolfo Favaretto and Vanesa Gregorc and Massimiliano Berretta and Sandra Santarossa and Eleonora Berto and Umberto Tirelli",
year = "2012",
doi = "10.1186/1756-0500-5-482",
language = "English",
volume = "5",
journal = "BMC Research Notes",
issn = "1756-0500",
publisher = "BioMed Central",

}

TY - JOUR

T1 - Re-challenge with pemetrexed in advanced mesothelioma

T2 - A multi-institutional experience

AU - Bearz, Alessandra

AU - Talamini, Renato

AU - Rossoni, Gilda

AU - Santo, Antonio

AU - De Pangher, Vincenzo

AU - Fasola, Gianpiero

AU - Rosetti, Francesco

AU - Favaretto, Adolfo

AU - Gregorc, Vanesa

AU - Berretta, Massimiliano

AU - Santarossa, Sandra

AU - Berto, Eleonora

AU - Tirelli, Umberto

PY - 2012

Y1 - 2012

N2 - Background: Although first-line therapy for patients affected by advanced mesothelioma is well established, there is a lack of data regarding the impact of second-line treatment. Methods. We retrospectively collected data of patients affected by advanced mesothelioma, already treated with first-line therapy based on pemetrexed and platin, with a response (partial response or stable disease) lasting at least 6 months, and re-treated with a pemetrexed-based therapy at progression. The primary objective was to describe time to progression and overall survival after re-treatment. Results: Overall across several Italian oncological Institutions we found 30 patients affected by advanced mesothelioma, in progression after a 6-month lasting clinical benefit following a first-line treatment with cisplatin and pemetrexed, and re-challenged with a pemetrexed-based therapy. In these patients we found a disease control rate of 66%, with reduction of pain in 43% of patients. Overall time to progression and survival were promising for a second-line setting of patients with advanced mesothelioma, being 5.1 and 13.6 months, respectively. Conclusions: In our opinion, when a patient has a long-lasting benefit from previous treatment with pemetrexed combined with a platin compound, the same treatment should be offered at progression.

AB - Background: Although first-line therapy for patients affected by advanced mesothelioma is well established, there is a lack of data regarding the impact of second-line treatment. Methods. We retrospectively collected data of patients affected by advanced mesothelioma, already treated with first-line therapy based on pemetrexed and platin, with a response (partial response or stable disease) lasting at least 6 months, and re-treated with a pemetrexed-based therapy at progression. The primary objective was to describe time to progression and overall survival after re-treatment. Results: Overall across several Italian oncological Institutions we found 30 patients affected by advanced mesothelioma, in progression after a 6-month lasting clinical benefit following a first-line treatment with cisplatin and pemetrexed, and re-challenged with a pemetrexed-based therapy. In these patients we found a disease control rate of 66%, with reduction of pain in 43% of patients. Overall time to progression and survival were promising for a second-line setting of patients with advanced mesothelioma, being 5.1 and 13.6 months, respectively. Conclusions: In our opinion, when a patient has a long-lasting benefit from previous treatment with pemetrexed combined with a platin compound, the same treatment should be offered at progression.

UR - http://www.scopus.com/inward/record.url?scp=84865598518&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84865598518&partnerID=8YFLogxK

U2 - 10.1186/1756-0500-5-482

DO - 10.1186/1756-0500-5-482

M3 - Article

C2 - 22943698

AN - SCOPUS:84865598518

VL - 5

JO - BMC Research Notes

JF - BMC Research Notes

SN - 1756-0500

M1 - 482

ER -